Skip to main content
. 2023 Jan 9;19(3):852–864. doi: 10.7150/ijbs.77434

Figure 3.

Figure 3

PAD4 and NOX targeting attenuate in-vivo cerebrovascular thrombosis. (A) Schematic representation of light/dye-induced thrombosis model induced with intravenous infusion of 10 mg/kg of 5% FITC-dextran followed by photoactivation of the cerebral microvessels of C57BL/6 mice. Time to flow cessation (minutes) was defined as the complete stop of blood flow for ≥ 30 seconds and was assessed in (B) arterioles and (C) venules in C57BL/6 mice treated with vehicle (saline. n=6 mice per group), GSK484 (10 μM. n=6 mice per group), VAS3847 (5 μM/ n=6 mice per group) or a combination of GSK484 + VAS3947 (n=5 mice per group). (D-E) Images of onset (start of platelet aggregation) and cessation (complete stop of flow for ≥30 seconds) in arterioles and venules respectively. **p<0.01, ***p<0.001, ****p<0.0001 vs. vehicle treated mice. Graphs are expressed as mean±SEM from 5-6 mice per group.